Helix Biopharma (OTCMKTS:HBPCF) Stock Falls 55.5% – Should You Sell?

Shares of Helix Biopharma Corp. (OTCMKTS:HBPCF) traded down 55.5% on Monday. The stock traded as low as $0.77 and last traded at $0.77. 200 shares changed hands during mid-day trading, The stock had previously closed at $1.73.

Helix Biopharma Trading Down 55.5%

The firm has a fifty day simple moving average of $1.69 and a 200-day simple moving average of $1.71. The stock has a market cap of $58.81 million, a price-to-earnings ratio of -19.25 and a beta of 0.18.

About Helix Biopharma

Helix BioPharma Corp. is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents.

The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth.